print PRINT

SCIENCE > Health

Avigan unlikely to be approved anytime soon

  • June 7, 2020
  • , Nikkei
  • JMH Summary

Sunday’s Nikkei front-paged a finding that clinical trials of the flu drug Avigan for coronavirus treatment will probably continue beyond July because of the lack of patients to take part in the trial. According to the daily, the drug manufacturer Fujifilm launched the trials in March with the goal of collecting data from a total of 96 patients. However, the firm has thus far gathered data from only about 70 patients. As the number of COVID-19 patients has plunged recently, the company has run into difficulties recruiting new subjects. As a result, the daily predicted that Avigan’s approval for COVID-19 treatment may be delayed until the summer or later.

  • Ambassador
  • Ukraine
  • COVID-19
  • Trending Japan